Merck won't partner with Gilead in mTNBC when they have their own TROP2 ADC, Sacituzumab tirumotecan. They are developing it as a monotherapy as well as in combination with pembro.

Late last year, Merck also jumped onto the PD-1/VEGF bispecific bandwagon with a licensing deal with a Chinese company.